CART-ddBCMA治疗复发难治性多发性骨髓瘤受试者的1期研究
这项单臂、开放标签1期研究纳入13例既往至少接受3线系统治疗的复发难治性多发性骨髓瘤患者,接受单次100×10^6或300×10^6 CART-ddBCMA输注。最大耐受剂量未达到,仅报告1例≥3级细胞因子释放综合征和1例免疫效应细胞相关神经毒性,均发生于DL2且经标准治疗可控;所有输注患者均缓解,9/12(75%)达完全缓解/严格完全缓解。
要点
- 13例复发难治性多发性骨髓瘤患者接受单次CART-ddBCMA输注,最大耐受剂量未达到
- 仅1例≥3级细胞因子释放综合征和1例免疫效应细胞相关神经毒性,均见于DL2且经标准治疗可控
- 所有输注患者均缓解,9/12(75%)达完全缓解/严格完全缓解,末次数据截止时8/9(89%)可评估患者微小残留病阴性
核心结论
- CART-ddBCMA细胞具有安全性,并在复发难治性多发性骨髓瘤患者中记录了持久缓解。
研究设计与样本
- 单臂、开放标签1期研究,纳入13例≥18岁、接受过至少3线系统治疗的复发难治性多发性骨髓瘤患者。
- 患者在接受标准淋巴细胞清除化疗后,单次输注100×10^6 CART-ddBCMA(DL1)或300×10^6 CART-ddBCMA(DL2)。
- 主要终点为治疗中出现的不良事件(包括剂量限制性毒性)发生率及确定推荐的2期剂量。
- 试验注册号为NCT04155749。
主要发现
- CART-ddBCMA耐受性良好,毒性特征良好。
- 仅报告1例≥3级细胞因子释放综合征和1例免疫效应细胞相关神经毒性,两者均发生于DL2且经标准治疗可控。
- 未观察到非典型神经毒性和帕金森病样运动障碍。
- 最大耐受剂量未达到。
- 所有输注患者均对CART-ddBCMA有缓解,9/12(75%)患者达完全缓解/严格完全缓解;缓解随时间加深,末次数据截止时(中位随访56周)8/9(89%)可评估患者达微小残留病阴性。
关键数值与推荐
- DL1为100×10^6 CART-ddBCMA,DL2为300×10^6 CART-ddBCMA。
- 9/12(75%)患者达完全缓解/严格完全缓解。
- 中位随访56周时,8/9(89%)可评估患者达微小残留病阴性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapsed and refractory multiple myeloma (RRMM) is a plasma cell neoplasm defined by progressively refractory disease necessitating chronic and increasingly intensive therapy. Despite recent advances, limited treatment options exist for RRMM. This single-arm, open label phase 1 study aimed to evaluate the safety of novel B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T construct that leverages a completely synthetic antigen-binding domain (CART-ddBCMA), which was specifically engineered to reduce immunogenicity and improve CAR cell surface stability. Thirteen patients ≥18 years with RRMM who received at least 3 prior regimens of systemic therapy were enrolled in the study. Patients received a single dose of 100 × 106 CART-ddBCMA (DL1) or 300 × 106 CART-ddBCMA (DL2) following standard lymphodepleting chemotherapy. The primary endpoints of the study were to evaluate the incidence of treatment emergent adverse events, including dose-limiting toxicities, and establish a recommended phase 2 dose. Results showed that CART-ddBCMA was well tolerated and demonstrated a favorable toxicity profile. Only 1 case of grade ≥3 cytokine release syndrome and 1 case of immune effector cell-associated neurotoxicity were reported; both were at DL2 and were manageable with standard treatment. No atypical neurological toxicities and Parkinson disease-like movement disorders were observed. The maximum tolerated dose was not reached. All infused patients responded to CART-ddBCMA, and 9/12 (75%) patients achieved complete response/stringent complete response. Responses deepened over time, and at the time of last data-cut (median follow-up 56 weeks), 8/9 (89%) evaluable patients achieved minimal residual disease negativity. In conclusion, the findings demonstrate the safety of CART-ddBCMA cells and document durable responses to CART-ddBCMA in patients with RRMM. This trial was registered at www.clinicaltrials.gov as #NCT04155749.
引用
- Frigault MJ, Bishop MR, Rosenblatt J, et al. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 2023. PMID: 35468618. doi:10.1182/bloodadvances.2022007210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。